Mitochondrial peptide comparison · September 24, 2026
SS-31 vs MOTS-c: same organelle, different mechanism.
SS-31 is a synthetic, membrane-directed tetrapeptide. MOTS-c is a mitochondrial-derived signaling peptide. Grouping both under “mitochondrial peptides” obscures the distinction that matters most.
THE SHORT ANSWER
One is framed around the membrane. The other is framed around signaling.
SS-31, or elamipretide, is a synthetic tetrapeptide studied for interactions at cardiolipin-rich inner mitochondrial membranes. MOTS-c is a peptide encoded within mitochondrial DNA and studied as a stress-responsive signal that can move to the nucleus and influence gene expression.
Both touch mitochondrial biology. They do not share the same origin, sequence, molecular target, evidence base, or regulatory status—and they should not be treated as substitutes.
SIDE-BY-SIDE
The clean comparison.
The table separates identity, mechanism, evidence, and regulatory status instead of reducing both peptides to a single mitochondria label.
| Question | SS-31Elamipretide | MOTS-cMitochondrial-derived peptide |
|---|---|---|
| What it is | A synthetic four-amino-acid peptide also called elamipretide | A 16-amino-acid peptide encoded within mitochondrial DNA |
| Primary mechanistic frame | Inner-mitochondrial-membrane and cardiolipin interactions | Mitochondrial-to-nuclear signaling during metabolic stress |
| Research emphasis | Membrane structure, cristae organization, respiration, and mitochondrial bioenergetics | AMPK-linked stress responses, gene regulation, and metabolic homeostasis |
| Human evidence | Clinical development plus an FDA accelerated-approval indication for Barth syndrome | Mechanistic, cell, animal, and limited human physiology evidence—not an approved drug component |
| Interchangeable? | No | No |
01 · SS-31
Membrane-directed and cardiolipin-associated.
SS-31 is a synthetic four-amino-acid peptide. Experimental work places it at the membrane-water interface and links its behavior to cardiolipin, a negatively charged phospholipid enriched in the inner mitochondrial membrane.
Cross-linking studies identified SS-31 interactions near proteins that also bind cardiolipin, including proteins involved in oxidative phosphorylation. Other biophysical work found that SS-31 can alter membrane surface electrostatics and lipid packing without simply acting as a generic antioxidant.
The careful conclusion: SS-31 research is centered on a cardiolipin-rich membrane environment and the mitochondrial machinery organized around it.
02 · MOTS-c
A mitochondrial-derived stress signal.
MOTS-c is a 16-amino-acid peptide encoded by a short open reading frame within the mitochondrial 12S rRNA region. That origin makes it fundamentally different from a synthetic mitochondria-targeting sequence such as SS-31.
Cell studies show that metabolic stress can trigger MOTS-c movement into the nucleus through an AMPK-dependent pathway. There, it has been reported to interact with stress-responsive transcriptional machinery and alter gene expression. Earlier animal work linked MOTS-c to metabolic homeostasis, but those findings do not automatically predict a clinical effect in people.
The careful conclusion: MOTS-c research is centered on mitochondrial-to-nuclear communication, stress response, and metabolic signaling.
EVIDENCE BOUNDARY
The regulatory gap is as important as the mechanism.
A narrow approved indication exists.
FDA granted accelerated approval to Forzinity (elamipretide) in September 2025 to improve muscle strength in adults and pediatric patients with Barth syndrome weighing at least 30 kilograms. Approval was based on an intermediate endpoint and requires confirmatory work. That decision does not establish elamipretide for fat loss, general performance, longevity, or every condition involving mitochondrial dysfunction.
Read the FDA announcement ↗Human drug evidence remains limited.
FDA’s July 2026 review of MOTS-c-related bulk substances states that neither MOTS-c nor MOTS-c acetate is a component of an FDA-approved drug. The agency identified major gaps in human exposure, effectiveness, safety, product characterization, and immunogenicity information for compounded products.
Read the FDA briefing document ↗WHAT THIS PAGE DOES NOT DO
A mechanism comparison is not a protocol.
- 01No dose conclusion — mechanistic studies do not choose an amount or schedule.
- 02No product conclusion — a peptide name does not establish identity, purity, content, sterility, endotoxin, or contaminants.
- 03No interchangeability claim — a shared mitochondria label does not make the compounds substitutes.
- 04No outcome promise — cell and animal findings do not automatically establish a human benefit.
COMMON QUESTIONS
Keep the name, mechanism, and evidence in separate columns.
Are SS-31 and MOTS-c the same peptide?
No. SS-31 is a synthetic tetrapeptide designed to target mitochondrial membranes. MOTS-c is a mitochondrial-derived 16-amino-acid peptide encoded within the mitochondrial genome.
Which peptide is also called elamipretide?
SS-31. Elamipretide is also the active ingredient in Forzinity, which received FDA accelerated approval for a specific Barth-syndrome indication in patients weighing at least 30 kilograms.
Does MOTS-c have an FDA-approved drug indication?
No. FDA’s 2026 compounding review states that MOTS-c and MOTS-c acetate are not components of an FDA-approved drug and identifies major gaps in human exposure, safety, and effectiveness evidence.
Do both peptides affect mitochondria?
They are both discussed in mitochondrial research, but that label hides a major distinction: SS-31 is studied primarily at the inner membrane and cardiolipin interface, while MOTS-c is studied as a mitochondria-derived stress signal that can alter nuclear gene expression.
Does this comparison establish a protocol or dose?
No. Mechanism, regulatory status, and study findings do not establish an individual protocol, product quality, safety, or suitability for use.
PRIMARY SOURCES
Research and regulatory records behind the comparison.
- Chavez et al., PNAS (2020) ↗Maps SS-31 interactions with cardiolipin-associated mitochondrial proteins.
- Mitchell et al., Journal of Physical Chemistry B (2020) ↗Examines SS-31 membrane binding, lipid packing, and surface electrostatics.
- Kim et al., Cell Metabolism (2018) ↗Reports stress-triggered MOTS-c nuclear translocation and gene regulation.
- Lee et al., Cell Metabolism (2015) ↗Describes the discovery of MOTS-c and preclinical metabolic findings.
- FDA Forzinity approval announcement ↗Defines elamipretide’s accelerated-approval indication and evidence boundary.
- FDA MOTS-c briefing document (2026) ↗Reviews the human-evidence, safety, characterization, and compounding gaps.
FREE TWO-PAGE REFERENCE
Keep the mechanism separate from the marketing claim.
Get the printable checklist, five common red flags, and a quick document-coverage guide. The PDF unlocks immediately after signup.
Instant PDF access. By subscribing, you agree to receive Compound IQ research education and occasional partner updates. Unsubscribe anytime.